Key result
GLP-1R agonists and mTOR inhibitors counteract brain aging in mice via shared and distinct pathways.
Why the study?
Effects of GLP-1RAs and mTOR inhibitors vary across brain regions, leaving their regional and neuronal subtype-specific mechanisms in aging unclear.
Answers are grounded in this paper and cite their sources.
GLP-1R agonism and mTOR inhibition induce distinct and shared region- and cell type-specific molecular changes that counteract brain aging in mice.
Brain aging is a major contributor to neurodegenerative diseases and is characterized by region- and cell type-specific molecular alterations. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and mammalian target of rapamycin inhibitors (mTORi), particularly rapamycin, have emerged as promising interventions against aging and age-related neurological disorders. GLP-1RAs exert systemic and brain-specific anti-aging effects, partly through hypothalamic GLP-1 receptor signaling, whereas mTOR inhibition promotes longevity and neuroprotection by enhancing autophagy, preserving vascular integrity and neuronal energy metabolism, and reducing pathological protein accumulation. Although these interventions induce convergent transcriptomic, epigenomic, and metabolomic changes, their effects vary across brain regions, suggesting distinct mechanisms and sites of action. Here, we investigate the regional and neuronal subtype-specific responses to GLP-1RA and mTORi treatment in the aging mouse brain. By integrating single-nucleus RNA sequencing with spatial transcriptomics, we map treatment-associated molecular signatures across diverse neuronal populations, circuits, and regions vulnerable to neurodegeneration. This approach identifies shared and distinct pathways through which GLP-1R agonism and mTOR inhibition counteract brain aging and provides mechanistic insight into their neuroprotective effects. These findings may inform the development of targeted anti-aging and therapeutic strategies tailored to the selective regional and cellular vulnerabilities underlying different neurodegenerative disorders.
No takes yet. Share an insight, caveat, or question.
Nenghan Lin (2026) studied Brain aging. GLP-1R agonists and mTOR inhibitors was evaluated on Regional and neuronal subtype-specific molecular signatures. GLP-1R agonism and mTOR inhibition counteract brain aging through shared and distinct pathways mapped across diverse neuronal populations and regions in the aging mouse brain.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: